fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Could penicillin allergy de-labelling lead to better outcomes?

Written by | 15 Nov 2023

Implementation of penicillin allergy de-labelling calls for an understanding of the key barriers and enablers in healthcare systems – topics that the iNAAN and ALABAMA studies address, explains… read more.

What the PALACE study tells us about penicillin allergy de-labelling

Written by | 14 Nov 2023

The PALACE study showed that in people at low-risk of penicillin allergy, a direct oral challenge with penicillin was no less effective than standard allergy testing for determining… read more.

Why penicillin allergy labels might be a bad thing

Written by | 13 Nov 2023

Neil Powell combines the roles of a consultant antimicrobial pharmacist and a clinical researcher at the Royal Cornwall Hospital in Truro.  His current research is focused on the… read more.

Establishing a community pharmacist-led vitamin D point-of-care testing service

Written by | 1 Nov 2023

Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently… read more.

What point-of-care testing for vitamin D levels tells us

Written by | 31 Oct 2023

The pilot study of pharmacist-led vitamin D point-of-care testing showed that the procedure was feasible in routine practice and, surprisingly, that more than half of participants had insufficient… read more.

Why should vitamin D levels be measured in community pharmacy?

Written by | 30 Oct 2023

Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently… read more.

STEP-HFpEF trial – caveats and implications

Written by | 19 Oct 2023

STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.

Semaglutide for prevention or cure of HFpEF?

Written by | 18 Oct 2023

The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.

How semaglutide impacts HFpEF

Written by | 17 Oct 2023

The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.

Could semaglutide help obese patients with heart failure?

Written by | 16 Oct 2023

STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.

Making sense of GLP-1 agonists

Written by | 29 Sep 2023

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.

What does a consultant pharmacist in diabetes do?

Written by | 28 Sep 2023

The work of a consultant pharmacist in diabetes spans clinical duties and leadership tasks including education and mentoring. There are at present only three consultant pharmacists in diabetes… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.